133 results
8-K
EX-99.1
ALLK
Allakos Inc
14 Mar 24
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:15pm
Allakos Anticipated Milestones
Report safety, pharmacokinetics (PK), and pharmacodynamic (PD) results from the Phase 1 trial of IV AK006 in healthy … -controlled Phase 1 trial of IV AK006 in patients with chronic spontaneous urticaria in Q2 2024.
Report safety, PK, and PD results from the Phase 1 trial
8-K
EX-99.1
ALLK
Allakos Inc
26 Feb 24
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
7:05am
in its clinical trials; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties
8-K
EX-99.1
ALLK
Allakos Inc
12 Feb 24
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
7:07am
; Allakos’ ability to demonstrate sufficient safety and efficacy of its product candidates in its clinical trials; uncertainties related to the success
8-K
EX-99.1
ALLK
Allakos Inc
16 Jan 24
Regulation FD Disclosure
6:17pm
, effectiveness and safety of our product candidates; our expectations with regard to the initiation, design, timing and results of our clinical studies … clinical trials; uncertainties related to the enrollment of patients in its clinical trials; the Company’s ability to demonstrate sufficient safety
8-K
EX-99.1
gkuor7lyuv
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm
8-K
EX-99.2
s966eaurzsxjq3
16 Jan 24
Allakos Announces a Restructuring to Focus on Development of AK006
5:00pm
8-K
EX-99.1
iy5z6dbi 5cx
13 Nov 23
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
hw0nzkz1zfx pdvsmf
30 Aug 23
Allakos Appoints Neil Graham to its Board of Directors
4:05pm
8-K
EX-99.1
u9d63n8 5pqn7optlq
9 Aug 23
Allakos Provides Business Update and Reports Second Quarter 2023 Financial Results
4:08pm
8-K
EX-99.1
6jpm1tmdn38gs
2 Aug 23
Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
4:03pm
8-K
EX-99.1
1pseib unex
12 Jun 23
Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
7:05am
8-K
EX-99.1
we7015x9w by
5 Jun 23
Other Events
7:12am
8-K
EX-99.1
ydvwb aetrj2
9 May 23
Allakos Provides Business Update and Reports First Quarter 2023 Financial Results
4:07pm
8-K
EX-99.1
pl9kjhpaj8 yfv1
29 Nov 22
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
7:05am
8-K
EX-99.1
ct5d2ybt9tmgicv97
10 Nov 22
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
9:09am